Hiroyuki Baba - Sumitomo Dainippon Executive Officer
| DNPUFDelisted Stock | USD 4.37 0.00 0.00% |
Executive
Hiroyuki Baba is Executive Officer of Sumitomo Dainippon Pharma since 2018.
| Age | 64 |
| Tenure | 7 years |
| Phone | 81 6 6203 5321 |
| Web | https://www.sumitomo-pharma.com |
Sumitomo Dainippon Management Efficiency
Sumitomo Dainippon's management efficiency ratios could be used to measure how well Sumitomo Dainippon manages its routine affairs as well as how well it operates its assets and liabilities.Sumitomo Dainippon Pharma has accumulated 243.96 B in total debt with debt to equity ratio (D/E) of 0.36, which is about average as compared to similar companies. Sumitomo Dainippon Pharma has a current ratio of 1.71, which is within standard range for the sector. Debt can assist Sumitomo Dainippon until it has trouble settling it off, either with new capital or with free cash flow. So, Sumitomo Dainippon's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sumitomo Dainippon Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sumitomo to invest in growth at high rates of return. When we think about Sumitomo Dainippon's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Chris Bitterman | Cumberland Pharmaceuticals | 60 | |
| Robert Cavorsi | Organogenesis Holdings | 46 | |
| Thomas Pearl | Organogenesis Holdings | N/A | |
| Jesper Lind | Orexo AB | 63 | |
| John Shulman | Petros Pharmaceuticals | 61 | |
| William CPA | Organogenesis Holdings | N/A | |
| Jean Marstiller | Cumberland Pharmaceuticals | 75 | |
| Brikkelle Thompson | Lifecore Biomedical | N/A | |
| Darren Hieber | Lifecore Biomedical | N/A | |
| Todd Anthony | Cumberland Pharmaceuticals | 64 | |
| Jennifer Henry | Alpha Teknova | N/A | |
| Erin Gull | Cumberland Pharmaceuticals | N/A | |
| John Hamm | Cumberland Pharmaceuticals | 68 | |
| Jackie Klecker | Lifecore Biomedical | N/A | |
| Kara Morley | Lifecore Biomedical | N/A | |
| Matt Augustson | Lifecore Biomedical | N/A | |
| Damon JD | Alpha Teknova | 55 | |
| Lena Wange | Orexo AB | N/A | |
| Steve Laninga | Lifecore Biomedical | N/A | |
| Nelson Mello | Hypera SA | 64 | |
Management Performance
| Return On Equity | -0.0399 | |||
| Return On Asset | -0.0075 |
Sumitomo Dainippon Pharma Leadership Team
Elected by the shareholders, the Sumitomo Dainippon's board of directors comprises two types of representatives: Sumitomo Dainippon inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sumitomo. The board's role is to monitor Sumitomo Dainippon's management team and ensure that shareholders' interests are well served. Sumitomo Dainippon's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sumitomo Dainippon's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hisayoshi Kashima, Director of Accounting | ||
| Yoshiharu Ikeda, Executive Officer, Chief Director of Technology Research | ||
| Hiroyuki Baba, Executive Officer | ||
| Toru Kimura, Executive Officer, Manager of Regeneration & Cell Medicine Business Promotion Office | ||
| Takuya Taguchi, Sr Unit | ||
| Hiroshi Nomura, Director | ||
| Hideyuki Harada, Executive Officer, Chief Director of Research | ||
| Atsuko Higuchi, Executive Officer | ||
| Shigeyuki Nishinaka, Executive Officer, Director of Business Development | ||
| Naoki Noguchi, Corp Governance |
Sumitomo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sumitomo Dainippon a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0399 | |||
| Return On Asset | -0.0075 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | (0.03) % | |||
| Current Valuation | 2.85 B | |||
| Shares Outstanding | 397.29 M | |||
| Shares Owned By Insiders | 58.59 % | |||
| Shares Owned By Institutions | 19.60 % | |||
| Price To Earning | 4.79 X | |||
| Price To Book | 0.64 X |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Other Consideration for investing in Sumitomo Pink Sheet
If you are still planning to invest in Sumitomo Dainippon Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sumitomo Dainippon's history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |